LB008/#180 KGOG3056/Nirvana-R Trial: Efficacy of Maintenance Niraparib Rechallenge Plus BEV According to Minimal Residual Disease (MRD) Assessment in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
International Journal of Gynecological Cancer（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined